Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Comment by harbroon May 08, 2012 4:18pm
188 Views
Post# 19886500

RE: RE: RE: Ex-DIV

RE: RE: RE: Ex-DIV

I sent and email today re the dividend and Mr Nutt responed as follows (props for the quick reply). I have trouble understanding why a "regular" dividend that has been recently increased after a tripling of profits and a strong balance sheet would need board review each quarter. Does this mean the dividend will vary each quarter?  I sure hope not!  The BOD needs to give mgt some authority on this kind of thing.

Mr. xxxxx

We are having a Board meeting this week to review Q1 results and discuss the quarterly dividend. You should expect to see a press release issued by the end of the week in this regards.

I acknowledge your concern about the timing of the dividend announcement and will review the potential for disclosing those dates in advance with the Board to eliminate confusion going forward. Simply put, we issued the Q1 dividend announcement earlier in Q1 as we did not want to delay the dividend while waiting for full audited results. For Q2, Q3 and Q4 I expect that everything else being equal we will be declaring dividends in conjunction with the release of the respective quarterly results.

Regards,

Christopher Nutt

President and CEO

Automodular Corporation

Bullboard Posts